Lancet’s EClinicalMedicine publishes phase 2 data on C21 in COVID-19
· The trial showed that C21 reduced the need for supplemental oxygen and mechanical ventilation, indicating faster patient recovery. C21 was also found to be safe and well tolerated. · Data encouraged Vicore to move into phase 3 with readout on-track for H1 2022.Gothenburg, October 25, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the results of the COVID-19 phase 2 trial of its angiotensin II type 2 receptor agonist C21 have been published in EClinicalMedicine, a